- Home
- LAC vs GHRS Comparison
LAC vs GHRS Comparison
Compare LAC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAC
- GHRS
- Stock Information
- Founded
- LAC 2023
- GHRS 2018
- Country
- LAC Canada
- GHRS Ireland
- Employees
- LAC N/A
- GHRS N/A
- Industry
- LAC Metal Mining
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- LAC Basic Materials
- GHRS Health Care
- Exchange
- LAC Nasdaq
- GHRS Nasdaq
- Market Cap
- LAC 722.6M
- GHRS 774.1M
- IPO Year
- LAC N/A
- GHRS 2021
- Fundamental
- Price
- LAC $5.86
- GHRS $14.00
- Analyst Decision
- LAC Hold
- GHRS Strong Buy
- Analyst Count
- LAC 8
- GHRS 9
- Target Price
- LAC $5.44
- GHRS $29.33
- AVG Volume (30 Days)
- LAC 75.4M
- GHRS 298.5K
- Earning Date
- LAC 11-07-2025
- GHRS 11-13-2025
- Dividend Yield
- LAC N/A
- GHRS N/A
- EPS Growth
- LAC N/A
- GHRS N/A
- EPS
- LAC N/A
- GHRS N/A
- Revenue
- LAC N/A
- GHRS N/A
- Revenue This Year
- LAC N/A
- GHRS N/A
- Revenue Next Year
- LAC N/A
- GHRS N/A
- P/E Ratio
- LAC N/A
- GHRS N/A
- Revenue Growth
- LAC N/A
- GHRS N/A
- 52 Week Low
- LAC $2.31
- GHRS $6.72
- 52 Week High
- LAC $10.52
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- LAC 45.05
- GHRS 54.05
- Support Level
- LAC $5.72
- GHRS $12.40
- Resistance Level
- LAC $7.00
- GHRS $14.54
- Average True Range (ATR)
- LAC 0.82
- GHRS 0.86
- MACD
- LAC -0.41
- GHRS 0.08
- Stochastic Oscillator
- LAC 2.11
- GHRS 65.96
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, which is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass is under construction and expected to begin production in 2028. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.